VA awards $130.5M for pharmaceutical preparations to McKesson Corporation under full and open competition
Contract Overview
Contract Amount: $130,506,095 ($130.5M)
Contractor: Mckesson Corporation
Awarding Agency: Department of Veterans Affairs
Start Date: 2012-12-01
End Date: 2012-12-31
Contract Duration: 30 days
Daily Burn Rate: $4.4M/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 5
Pricing Type: FIRM FIXED PRICE
Sector: Healthcare
Official Description: EXPRESS REPORT + PHARMACEUTICALS
Place of Performance
Location: MURFREESBORO, RUTHERFORD County, TENNESSEE, 37130
Plain-Language Summary
Department of Veterans Affairs obligated $130.5 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT + PHARMACEUTICALS Key points: 1. Significant contract value of $130.5 million awarded. 2. McKesson Corporation is a major player in the pharmaceutical distribution market. 3. Full and open competition was utilized, suggesting a robust price discovery process. 4. The contract falls within the pharmaceutical preparation manufacturing sector.
Value Assessment
Rating: good
The contract's firm fixed price structure provides cost certainty. Benchmarking against similar pharmaceutical supply contracts would offer further insight into value.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The use of full and open competition indicates that multiple vendors had the opportunity to bid, fostering a competitive environment that should drive favorable pricing.
Taxpayer Impact: Taxpayer funds are being utilized through a competitive process, aiming for cost-effectiveness in pharmaceutical procurement.
Public Impact
Ensures access to essential pharmaceuticals for veterans. Supports the Department of Veterans Affairs' healthcare mission. Impacts the pharmaceutical supply chain and distribution network.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Potential for price fluctuations in pharmaceutical markets.
- Dependence on a single awardee for a large value contract.
Positive Signals
- Competitive award process.
- Clear contract type (firm fixed price).
Sector Analysis
This contract is within the pharmaceutical preparation manufacturing sector, which is critical for healthcare. Spending benchmarks in this area are often high due to the nature of medical supplies.
Small Business Impact
The data does not indicate specific small business participation. Further analysis would be needed to determine if small businesses were involved as subcontractors or prime contractors.
Oversight & Accountability
The Department of Veterans Affairs is responsible for oversight. Contract performance and adherence to terms would be monitored to ensure accountability.
Related Government Programs
- Pharmaceutical Preparation Manufacturing
- Department of Veterans Affairs Contracting
- Department of Veterans Affairs Programs
Risk Flags
- Market volatility in pharmaceutical pricing.
- Potential for supply chain disruptions.
- Contract duration and renewal risks.
- Dependence on a single large supplier.
Tags
pharmaceutical-preparation-manufacturing, department-of-veterans-affairs, tn, delivery-order, 100m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Veterans Affairs awarded $130.5 million to MCKESSON CORPORATION. EXPRESS REPORT + PHARMACEUTICALS
Who is the contractor on this award?
The obligated recipient is MCKESSON CORPORATION.
Which agency awarded this contract?
Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).
What is the total obligated amount?
The obligated amount is $130.5 million.
What is the period of performance?
Start: 2012-12-01. End: 2012-12-31.
What is the historical pricing trend for similar pharmaceutical preparations procured by the VA?
Analyzing historical pricing data for comparable pharmaceutical preparations procured by the VA is crucial. This would involve comparing the awarded price against previous contracts for similar items, considering factors like inflation, market demand, and specific drug formulations. Such a comparison helps determine if the current award represents a fair and reasonable price over time and identifies any significant deviations that warrant further investigation.
What are the key performance indicators (KPIs) for this contract and how is performance being measured?
Key performance indicators for this contract likely include on-time delivery, product quality and compliance with specifications, and order accuracy. The VA would establish specific metrics and thresholds for these KPIs. Performance is typically measured through regular reporting by the contractor, inspections, and user feedback. Failure to meet KPIs could result in penalties or contract termination, ensuring accountability.
How does the awarded price compare to the government estimate or other competitive bids received?
Comparing the awarded price to the government's independent cost estimate and other bids received is essential for validating value. If the awarded price is significantly lower than the estimate and other bids, it suggests strong competition and good price discovery. Conversely, if it's higher, it may indicate issues with the bidding process or market conditions. This comparison is a primary method for assessing procurement effectiveness.
Industry Classification
NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing
Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE
Offers Received: 5
Pricing Type: FIRM FIXED PRICE (J)
Evaluated Preference: NONE
Contractor Details
Address: ONE POST ST, SAN FRANCISCO, CA, 94104
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $130,506,095
Exercised Options: $130,506,095
Current Obligation: $130,506,095
Contract Characteristics
Commercial Item: COMMERCIAL ITEM
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: VA797P12D0001
IDV Type: IDC
Timeline
Start Date: 2012-12-01
Current End Date: 2012-12-31
Potential End Date: 2012-12-31 00:00:00
Last Modified: 2019-08-20
More Contracts from Mckesson Corporation
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 November — $1.4B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 October — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 September — $1.2B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2025 July — $1.1B (Department of Veterans Affairs)
- Express Report: Pharmaceutical Prime Vendor (ppv)fy2026 December — $1.1B (Department of Veterans Affairs)
Other Department of Veterans Affairs Contracts
- CCN Region 3 Express Report — $5.2B (Optum Public Sector Solutions, Inc.)
- Express Report for FY22 Region 2 — $5.1B (Optum Public Sector Solutions, Inc.)
- Fiscal Year 2022 Express Report for Region 1 — $4.2B (Optum Public Sector Solutions, Inc.)
- Express Report for the Patient Centered Community Care (PC3) Contract — $3.3B (Triwest Healthcare Alliance Corp)
- CCN Region Three FY21 Express Report — $3.1B (Optum Public Sector Solutions, Inc.)